Safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of randomized clinical trials

Current Medical Research and Opinion

Volumn 27, Issue SUPPL. 3, 2011, Pages 57-64

  Monami, Matteo ^a   Dicembrini, Ilaria ^a   Martelli, Daniele ^a   Mannucci, Edoardo ^b  

^a Careggi Teaching Hospital   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cancer; Dipeptidyl peptidase 4; Major cardiovascular events; Meta analysis; Type 2 diabetes

Indexed keywords

ACARBOSE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ARTICLE; BREAST DISEASE; CANCER RISK; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; EMBASE; GASTROINTESTINAL DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PANCREAS DISEASE; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; THYROID DISEASE; TREATMENT DURATION; UROGENITAL TRACT DISEASE;

DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; INTERNET; MALE; MEDLINE; NEOPLASMS, SECOND PRIMARY; PANCREATITIS; RANDOM ALLOCATION; RISK FACTORS; TIME FACTORS;

EID: 81855194761     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.602964     Document Type: Article

References (20)

1. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206 (Pubitemid 47057766)
2. Monami M, Iacomelli I, Marchionni N, et al. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35
3. FDA Endocrinological and Metabolic Drugs Advisory Committee. FDA guideline for enddocrinologic and metabolic drugs. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/Commi t teesMeet ingMater ials/Drugs/Endocr inologicandMetabol icDrugsAdvisoryCommittee/UCM148659.pdf [Last accessed 15 March 2011]
4. Elashoff M, Matveyenko AV, Gier B, et al. Increased incidence of pancreatitis and cancer among patients given glucagon like peptide-1 based therapy. Gastroenterology 2011;141:150-6
5. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12 (Pubitemid 26120810)
6. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
7. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34 (Pubitemid 27387172)
8. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29
9. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9
10. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7
11. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010;53:1-6
12. Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell research 2005;15:72-7 (Pubitemid 41653970)
13. Koehler JA, Baggio LL, Lamont BJ, et al. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009;58:2148-61
14. Tatarkiewicz K, Smith PA, Sablan EJ, et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metabol 2010;299:E1076-86
15. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
16. Ligueros-Saylan M, Foley JE, Schweizer A, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Diabetes Obes Metabol. 2010;12:495-509
17. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010; 64:984-90
18. Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metabol 2010;12:485-94
19. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
20. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011:215764